Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

13.32
+0.14001.06%
Volume:112.39K
Turnover:1.51M
Market Cap:501.11M
PE:-7.74
High:13.76
Open:13.41
Low:12.94
Close:13.18
52wk High:17.79
52wk Low:8.60
Shares:37.62M
Float Shares:31.54M
Volume Ratio:0.97
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7201
EPS(LYR):-2.1700
ROE:-28.01%
ROA:-19.15%
PB:2.09
PE(LYR):-6.14

Loading ...

Jones sees greater room for Contineum’s PIPE-791 to differentiate

TIPRANKS
·
Oct 01

Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

TIPRANKS
·
Sep 30

Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from JonesTrading

TIPRANKS
·
Sep 30

Contineum Therapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
Sep 30

NASDAQ Trade Halt Volatility Trading Pause at 03:50 Pm

Reuters
·
Sep 30

Contineum price target lowered to $17 from $18 at Morgan Stanley

TIPRANKS
·
Sep 28

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTrading

TIPRANKS
·
Sep 28

RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)

TIPRANKS
·
Sep 22

RBC Cuts Price Target on Contineum Therapeutics to $21 From $23, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)

TIPRANKS
·
Sep 19

Shares of Contineum Down 9.9% After J&J-Partnered Depression Drug Fails Mid-Stage Trial

THOMSON REUTERS
·
Sep 16

Contineum Therapeutics Price Target Cut to $24.00/Share from $26.00 by Jones Trading

Dow Jones
·
Sep 15

LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State

Reuters
·
Sep 15

LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump

Reuters
·
Sep 15

Contineum price target lowered to $19 from $20 at Baird

TIPRANKS
·
Sep 15

Contineum Therapeutics, Inc. : Leerink Partners Cuts Target Price to $22 from $25

THOMSON REUTERS
·
Sep 15

Stocks to Watch: Dave & Buster's, Contineum, Boxlight, Kestra Medical

Dow Jones
·
Sep 15

Analyst Maintains Buy on Contineum, Trims Price Target to $23 Following PIPE-307 Setback While PIPE-791 IPF Program Remains Core Value Driver

TIPRANKS
·
Sep 15

Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback

TIPRANKS
·
Sep 15

Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint

MT Newswires Live
·
Sep 15